https://www.selleckchem.com/pr....oducts/anidulafungin
The analysis revealed an adjusted HR of 0.80 (95% CI, 0.78-0.83) for the development of dementia among those with symptomatic HSV relative to those without. Among the 61,776 HSV-1/HSV-2 patients who were treated with antiherpetic medication, 4836 patients (7.8%) developed dementia (adjusted HR = 0.75; 95% CI, 0.72-0.78); this translated to a population average of one additional year of being dementia free in those who were taking antiherpetic medication. In contrast to Tzeng et al. we did not find that HSV infection was a
Like
Comment
Share
